ATE229943T1 - Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen - Google Patents
Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminenInfo
- Publication number
- ATE229943T1 ATE229943T1 AT98105754T AT98105754T ATE229943T1 AT E229943 T1 ATE229943 T1 AT E229943T1 AT 98105754 T AT98105754 T AT 98105754T AT 98105754 T AT98105754 T AT 98105754T AT E229943 T1 ATE229943 T1 AT E229943T1
- Authority
- AT
- Austria
- Prior art keywords
- substituted
- imidazo
- amines
- quinoline
- production
- Prior art date
Links
- 239000013067 intermediate product Substances 0.000 title 1
- -1 alkylamido Chemical group 0.000 abstract 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000005740 tumor formation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Lubricants (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66292691A | 1991-03-01 | 1991-03-01 | |
| US68732691A | 1991-04-18 | 1991-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE229943T1 true ATE229943T1 (de) | 2003-01-15 |
Family
ID=27098631
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98105754T ATE229943T1 (de) | 1991-03-01 | 1992-02-20 | Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen |
| AT92906763T ATE179711T1 (de) | 1991-03-01 | 1992-02-20 | 1,2-substituierte 1h-imidazo(4,5-c>chinolin-4- amine |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92906763T ATE179711T1 (de) | 1991-03-01 | 1992-02-20 | 1,2-substituierte 1h-imidazo(4,5-c>chinolin-4- amine |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP0582581B1 (de) |
| JP (1) | JP2955019B2 (de) |
| AT (2) | ATE229943T1 (de) |
| AU (2) | AU658621B2 (de) |
| CA (2) | CA2289219C (de) |
| CZ (1) | CZ285050B6 (de) |
| DE (2) | DE69229114T2 (de) |
| DK (2) | DK0872478T3 (de) |
| ES (2) | ES2131070T3 (de) |
| HU (5) | HU222251B1 (de) |
| IE (1) | IE920605A1 (de) |
| IL (2) | IL114570A (de) |
| NO (1) | NO303729B1 (de) |
| NZ (1) | NZ241784A (de) |
| PH (1) | PH31614A (de) |
| SG (2) | SG70625A1 (de) |
| UA (1) | UA32546C2 (de) |
| WO (1) | WO1992015582A1 (de) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266575A (en) * | 1991-11-06 | 1993-11-30 | Minnesota Mining And Manufacturing Company | 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines |
| US5395937A (en) * | 1993-01-29 | 1995-03-07 | Minnesota Mining And Manufacturing Company | Process for preparing quinoline amines |
| US5352784A (en) * | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| US5648516A (en) * | 1994-07-20 | 1997-07-15 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| CZ288182B6 (en) * | 1993-07-15 | 2001-05-16 | Minnesota Mining & Mfg | Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon |
| US5482936A (en) * | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| US6133547A (en) * | 1996-09-05 | 2000-10-17 | Medtronic, Inc. | Distributed activator for a two-dimensional shape memory alloy |
| US5939090A (en) * | 1996-12-03 | 1999-08-17 | 3M Innovative Properties Company | Gel formulations for topical drug delivery |
| JPH10298181A (ja) * | 1997-04-25 | 1998-11-10 | Sumitomo Pharmaceut Co Ltd | タイプ２ヘルパーｔ細胞選択的免疫応答抑制剤 |
| EP1541572A1 (de) * | 2000-12-08 | 2005-06-15 | 3M Innovative Properties Company | Thioether substituierte Imidazochinoline |
| UA74593C2 (en) * | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
| US6664264B2 (en) * | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| UA74852C2 (en) * | 2000-12-08 | 2006-02-15 | 3M Innovative Properties Co | Urea-substituted imidazoquinoline ethers |
| GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| JP2006502121A (ja) * | 2002-07-23 | 2006-01-19 | テバ ジョジセルジャール レースベニュタールシャシャーグ | １Ｈ−イミダゾ［４，５−ｃ］キノリン−４−フタルイミド中間体を介する１Ｈ−イミダゾ−［４，５−ｃ］キノリン−４−アミンの調製 |
| AR046046A1 (es) | 2003-10-03 | 2005-11-23 | 3M Innovative Properties Co | Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas. |
| MXPA06005910A (es) | 2003-11-25 | 2006-08-23 | 3M Innovative Properties Co | Sistemas de anillo imidazo sustituido y metodos. |
| EP1765348B1 (de) * | 2004-06-18 | 2016-08-03 | 3M Innovative Properties Company | Substituierte imidazochinoline, imidazopyridine sowie imidazonaphthyridine |
| US8080560B2 (en) | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
| CA2597092A1 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune reponse modifiers |
| SI1858920T1 (sl) | 2005-02-18 | 2016-07-29 | Glaxosmithkline Biologicals S.A. | Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso |
| NZ580974A (en) | 2005-02-18 | 2011-05-27 | Novartis Vaccines & Diagnostic | Immunogens from uropathogenic escherichia coli |
| US8158794B2 (en) | 2005-02-23 | 2012-04-17 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
| JP2008543725A (ja) | 2005-02-23 | 2008-12-04 | コーリー ファーマシューティカル グループ，インコーポレイテッド | ヒドロキシアルキル置換イミダゾキノリン |
| AU2006216686A1 (en) | 2005-02-23 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Method of preferentially inducing the biosynthesis of interferon |
| JP2008538550A (ja) | 2005-04-01 | 2008-10-30 | コーリー ファーマシューティカル グループ，インコーポレイテッド | ウイルス感染および腫瘍性疾患を処置するためのサイトカイン生合成の調節因子としての１−置換ピラゾロ（３，４−ｃ）環状化合物 |
| JP5247458B2 (ja) * | 2005-11-04 | 2013-07-24 | スリーエム・イノベイティブ・プロパティーズ・カンパニー | ヒドロキシ及びアルコキシ置換１ｈ−イミダゾキノリン及び方法 |
| PL1951299T3 (pl) | 2005-11-04 | 2012-07-31 | Novartis Ag | Szczepionki przeciw grypie zawierające kombinacje adiuwantów cząsteczkowych i czynników wzmacniających immunogenność |
| CN102755645A (zh) | 2005-11-04 | 2012-10-31 | 诺华疫苗和诊断有限公司 | 佐剂配制的包含细胞因子诱导剂的流感疫苗 |
| PL1945252T3 (pl) | 2005-11-04 | 2013-11-29 | Seqirus Uk Ltd | Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant |
| US20090304742A1 (en) | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
| KR20080089663A (ko) | 2006-01-27 | 2008-10-07 | 노바티스 백신즈 앤드 다이아그노스틱스 게엠베하 운트 콤파니 카게 | 적혈구응집소 및 기질 단백질을 함유한 인플루엔자 백신 |
| JP2009534303A (ja) | 2006-03-24 | 2009-09-24 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 冷蔵しないインフルエンザワクチンの保存 |
| SG173336A1 (en) | 2006-03-31 | 2011-08-29 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
| DK2054431T3 (da) | 2006-06-09 | 2012-01-02 | Novartis Ag | Konformere af bakterielle adhæsiner |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| AU2007279376B2 (en) | 2006-07-31 | 2012-09-06 | Wirra Ip Pty Ltd | Immune response modifier compositions and methods |
| EP2586790A3 (de) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogene von uropathogenen Escherichia coli |
| WO2008032219A2 (en) | 2006-09-11 | 2008-03-20 | Novartis Ag | Making influenza virus vaccines without using eggs |
| CN101553252A (zh) | 2006-12-06 | 2009-10-07 | 诺华有限公司 | 包含来自于四株流感病毒的抗原的疫苗 |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| AU2008247165B2 (en) * | 2007-05-08 | 2011-11-03 | Astrazeneca Ab | Imidazoquinolines with immuno-modulating properties |
| HRP20120790T1 (hr) | 2007-06-27 | 2013-01-31 | Novartis Ag | Cjepiva protiv influence sa niskom koliäśinom aditiva |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| EA018068B1 (ru) * | 2008-03-03 | 2013-05-30 | Айрм Ллк | Соединения и композиции в качестве модуляторов активности tlr |
| ES2535101T3 (es) | 2008-03-18 | 2015-05-05 | Novartis Ag | Mejoras en la preparación de antígenos en vacuna de virus de la gripe |
| MX344330B (es) * | 2008-03-24 | 2016-12-13 | 4Sc Ag | Imidazoquinolinas substituidas novedosas. |
| CN102438650A (zh) | 2009-03-06 | 2012-05-02 | 诺华有限公司 | 衣原体抗原 |
| WO2010119343A2 (en) | 2009-04-14 | 2010-10-21 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| CA2763816A1 (en) | 2009-04-27 | 2010-11-04 | Novartis Ag | Adjuvanted vaccines for protecting against influenza |
| ES2662716T3 (es) | 2009-07-07 | 2018-04-09 | Glaxosmithkline Biologicals Sa | Inmunógenos conservados de Escherichia coli |
| PL3178490T3 (pl) | 2009-07-15 | 2022-08-01 | Glaxosmithkline Biologicals S.A. | Kompozycje białka f rsv i sposoby ich wytwarzania |
| AU2010272243A1 (en) | 2009-07-16 | 2012-03-08 | Novartis Ag | Detoxified Escherichia coli immunogens |
| GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| WO2011084725A1 (en) * | 2009-12-21 | 2011-07-14 | 3M Innovative Properties Company | 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS |
| WO2011084726A1 (en) * | 2009-12-21 | 2011-07-14 | 3M Innovative Properties Company | BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS |
| JP5781542B2 (ja) | 2009-12-30 | 2015-09-24 | ノバルティス アーゲー | Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原 |
| WO2011150258A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| US20130243841A1 (en) | 2010-06-01 | 2013-09-19 | Novartis Ag | Concentration of vaccine antigens with lyophilization |
| DK2575872T3 (da) | 2010-06-01 | 2020-10-19 | Seqirus Uk Ltd | Koncentrering af influenzavaccineantigener uden frysetørring |
| GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
| US9517205B2 (en) | 2010-08-20 | 2016-12-13 | Seqirus UK Limited | Soluble needle arrays for delivery of influenza vaccines |
| EA201390660A1 (ru) | 2010-11-05 | 2013-11-29 | Селекта Байосайенсиз, Инк. | Модифицированные никотиновые соединения и связанные способы |
| PL2667892T3 (pl) | 2011-01-26 | 2019-09-30 | Glaxosmithkline Biologicals Sa | Schemat szczepień przeciwko rsv |
| ES2651143T3 (es) | 2011-05-13 | 2018-01-24 | Glaxosmithkline Biologicals Sa | Antígenos de F de prefusión del VRS |
| US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
| EP2729178A1 (de) | 2011-07-08 | 2014-05-14 | Novartis AG | Tyrosinverbindungsverfahren |
| US9493517B2 (en) | 2011-11-07 | 2016-11-15 | Glaxosmithkline Biologicals Sa | Conjugates comprising an antigen and a carrier molecule |
| WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
| CA2885625A1 (en) | 2012-10-02 | 2014-04-10 | Glaxosmithkline Biologicals S.A. | Nonlinear saccharide conjugates |
| SMT201800011T1 (it) | 2012-11-30 | 2018-05-02 | Glaxosmithkline Biologicals Sa | Antigeni e combinazioni di antigeni di pseudomonas |
| DK2950649T3 (da) | 2013-02-01 | 2020-05-04 | Wellstat Therapeutics Corp | Aminforbindelser med antiinflammations-, antisvampe-, antiparasit- og anticanceraktivitet |
| EP2870974A1 (de) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella-Konjugatimpfstoffe |
| EA037818B1 (ru) | 2014-03-26 | 2021-05-25 | Глаксосмитклайн Байолоджикалс С.А. | Мутантные стафилококковые антигены |
| PL3134402T3 (pl) | 2014-04-22 | 2020-11-02 | F.Hoffmann-La Roche Ag | Związki 4-amino-imidazochinolinowe |
| PE20171456A1 (es) | 2015-03-06 | 2017-10-06 | Hoffmann La Roche | Compuestos de dicarboxamida de benzazepinas |
| CN108137586B (zh) * | 2015-09-14 | 2021-04-13 | 辉瑞大药厂 | 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物 |
| JP6893501B2 (ja) | 2015-09-17 | 2021-06-23 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | スルフィニルフェニル又はスルホンイミドイルフェニルベンザゼピン |
| JP6918838B2 (ja) | 2016-05-23 | 2021-08-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 第三級アミド基を有するベンズアゼピンジカルボキサミド化合物 |
| JP7022702B2 (ja) | 2016-05-23 | 2022-02-18 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 第二級アミド基を有するベンズアゼピンジカルボキサミド化合物 |
| EP3468963B1 (de) | 2016-06-12 | 2021-10-27 | F. Hoffmann-La Roche AG | Dihydropyrimidinyl-benzazepincarboxamide verbindungen |
| TWI674261B (zh) * | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| CA3063953A1 (en) * | 2017-05-19 | 2018-11-22 | Superb Wisdom Limited | Derivatives of resiquimod |
| KR20200019226A (ko) | 2017-06-23 | 2020-02-21 | 버디 바이오파마슈티칼즈, 인크. | 약학 조성물 |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1271477A (en) * | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| EP0385630B1 (de) * | 1989-02-27 | 1996-11-27 | Riker Laboratories, Inc. | 4-Amino-1H-Imidazo(4,5-c)chinoline als antivirale Mittel |
-
1992
- 1992-02-20 EP EP92906763A patent/EP0582581B1/de not_active Expired - Lifetime
- 1992-02-20 DK DK98105754T patent/DK0872478T3/da active
- 1992-02-20 AU AU15669/92A patent/AU658621B2/en not_active Expired
- 1992-02-20 UA UA94020490A patent/UA32546C2/uk unknown
- 1992-02-20 CA CA002289219A patent/CA2289219C/en not_active Expired - Lifetime
- 1992-02-20 SG SG1998000326A patent/SG70625A1/en unknown
- 1992-02-20 HU HU9701084A patent/HU222251B1/hu not_active IP Right Cessation
- 1992-02-20 CA CA002104782A patent/CA2104782C/en not_active Expired - Lifetime
- 1992-02-20 WO PCT/US1992/001305 patent/WO1992015582A1/en not_active Ceased
- 1992-02-20 AT AT98105754T patent/ATE229943T1/de not_active IP Right Cessation
- 1992-02-20 EP EP98105754A patent/EP0872478B1/de not_active Expired - Lifetime
- 1992-02-20 AT AT92906763T patent/ATE179711T1/de not_active IP Right Cessation
- 1992-02-20 JP JP4506455A patent/JP2955019B2/ja not_active Expired - Lifetime
- 1992-02-20 DE DE69229114T patent/DE69229114T2/de not_active Expired - Lifetime
- 1992-02-20 ES ES92906763T patent/ES2131070T3/es not_active Expired - Lifetime
- 1992-02-20 HU HU9302457A patent/HU222111B1/hu not_active IP Right Cessation
- 1992-02-20 ES ES98105754T patent/ES2186034T3/es not_active Expired - Lifetime
- 1992-02-20 DE DE69232878T patent/DE69232878T2/de not_active Expired - Fee Related
- 1992-02-20 HU HU9701083A patent/HU222247B1/hu not_active IP Right Cessation
- 1992-02-20 HU HU9701089A patent/HU222250B1/hu not_active IP Right Cessation
- 1992-02-20 DK DK92906763T patent/DK0582581T3/da active
- 1992-02-20 CZ CZ931788A patent/CZ285050B6/cs not_active IP Right Cessation
- 1992-02-20 SG SG1996005108A patent/SG46492A1/en unknown
- 1992-02-26 IE IE060592A patent/IE920605A1/en not_active IP Right Cessation
- 1992-02-28 NZ NZ241784A patent/NZ241784A/en not_active IP Right Cessation
- 1992-02-28 PH PH43994A patent/PH31614A/en unknown
- 1992-03-01 IL IL11457092A patent/IL114570A/en not_active IP Right Cessation
- 1992-03-01 IL IL10111092A patent/IL101110A/en not_active IP Right Cessation
-
1993
- 1993-08-27 NO NO933069A patent/NO303729B1/no not_active IP Right Cessation
-
1995
- 1995-07-03 HU HU95P/P00753P patent/HU211242A9/hu unknown
- 1995-07-25 AU AU27157/95A patent/AU673309B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE229943T1 (de) | Zwischenprodukte zur herstellung von 1- substituierten, 2-substituierten-1h-imidazo(4,5- c)chinolin-4-aminen | |
| ATE18048T1 (de) | Carbapenem-derivate, ihre herstellung und sie enthaltende zusammensetzungen. | |
| NO304946B1 (no) | Xantinderivat samt dets anvendelse | |
| PT920430E (pt) | Derivados de purina e sua utilizacao como anticoagulantes | |
| TW221814B (de) | ||
| NZ333706A (en) | Benzenesulfone derivatives and medicaments | |
| AU6947401A (en) | Phenylpyridazine derivatives and drugs containing the same | |
| MY141488A (en) | Hydroximic acid derivatives, processes for their preparation, and compositions comprising them | |
| DK0579968T3 (da) | 4-Iminoquinoliner, fremgangsmåde til deres fremstilling og deres anvendelse | |
| DE69614102D1 (de) | Pyrazol[1,5-a]pyrimidin derivate | |
| ATE165815T1 (de) | N-phenyl-2-cyano-3-hydroxypropenamide, ihre tautomeren, ihre salze, verfahren zu ihrer herstellung, ihre anwendung als medikamente und zusammensetzungen, die sie enthalten | |
| EP0551844A3 (de) | ||
| DE69218718D1 (de) | Pharmazeutische Zusammensetzungen die Triazole Derivate enthalten zur rektalen Verabbrechung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0872478 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |